Hoffman MK, Goudar SS, Kodkany BS, et al. - A randomized, double-blind, placebo-controlled trial was designed to evaluate the utility and safety of low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy. A total of 14,361 women were selected for inclusion and 11,976 women aged 14–40 years were allocated randomly to receive low-dose aspirin (5,990 women) or placebo (5986 women) between March 23, 2016, and June 30, 2018. In the aspirin group, 5,780 women and in the placebo group, 5,764 women were evaluable for the primary outcome. The data indicated that low-dose aspirin initiated between 6 weeks and 0 days of gestation and 13 weeks and 6 days of gestation occurred in a lowered incidence of preterm delivery before 37 weeks and decreased perinatal mortality, in populations of nulliparous women with singleton pregnancies from low-income and middle-income countries.